Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Inhibiting Drp1 Dependent Mitochondrial Fission

Priyanka Sharma, Lauren B. Ostermann, Sujan Piya, Baozhen Ke, Natalia Baran, Anudishi Tyagi, Muharrem Muftuoglu, Mahesh Basyal, Qi Zhang, Joanne Munck, Kim-Hien Dao, Martin Sims, Bing Z. Carter, Venkata Lokesh Battula, Michael Andreeff, Gautam Borthakur

Blood (2023) 142 (Supplement 1): 412.

https://doi.org/10.1182/blood-2023-185700

Published: 2023

Journal Articles

A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis

Abhishek Maiti, Naval Daver, Swami P. Iyer, David McCall, Satyen H Gohil, Javier Lopez Jimenez, Hayley Lane, Benjamin Kim, Kim-Hien Dao, Gary Patou, Sandip Panicker, Kelly Covert, Graham Carl Parry, Carl E Allen

Blood (2023) 142 (Supplement 1): 1162.

https://doi.org/10.1182/blood-2023-177795

Published: 2023

Journal Articles

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Blood (2022) 140 (Supplement 1): 2066–2069.

https://doi.org/10.1182/blood-2022-163841

Published: 2022

Journal Articles

ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Altering Drp1-Dependent Mitochondrial Fission and Metabolism

Priyanka Sharma, Sujan Piya, Natalia Baran, Anna Zal, Christopher J. Hindley, Kim-Hien Dao, Martin Sims, Tomasz Zal, Vivian Ruvolo, Michael Andreeff, Gautam Borthakur

Blood (2022) 140 (Supplement 1): 8789–8790.

https://doi.org/10.1182/blood-2022-167171

Published: 2022

Journal Articles

Inhibition of ERK1/2 Reverses Venetoclax-Induced Autophagy to Overcome Resistance in Acute Myeloid Leukemia

Priyanka Sharma, Sujan Piya, Natalia Baran, Muharrem Muftuoglu, Mahesh Basyal, Vivian Ruvolo, Christopher J. Hindley, Kim-Hien Dao, Martin Sims, Michael Andreeff, Gautam Borthakur

Blood (2022) 140 (Supplement 1): 3093–3094.

https://doi.org/10.1182/blood-2022-165552

Published: 2022

Journal Articles

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

Blood (2021) 138 (Supplement 1): 66.

https://doi.org/10.1182/blood-2021-144648

Published: 2021

Journal Articles

A Phase 1 Study Evaluating ASTX727 (decitabine and cedazuridine) and Venetoclax Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction Chemotherapy

Gabriel N. Mannis, Elizabeth A. Griffiths, Michael R. Savona, Olatoyosi Odenike, Gail J. Roboz, Casey L. O'Connell, Jacqueline Dillingham, Prieya Wason, Lixia Zhu, Danna Chan, Harold N. Keer, Aram Oganesian, Kim-Hien Dao, Courtney D. DiNardo

Blood (2021) 138 (Supplement 1): 1245.

https://doi.org/10.1182/blood-2021-146264

Published: 2021

Journal Articles

ERK1/2 Inhibition Overcomes Resistance in Acute Myeloid Leukemia (AML) and Alters Mitochondrial Dynamics

Priyanka Sharma, Sujan Piya, Huaxian Ma, Natalia Baran, Malgorzata Anna Zal, Christopher J. Hindley, Kim-Hien Dao, Martin Sims, Tomasz Zal, Vivian Ruvolo, Michael Andreeff, Gautam Borthakur

Blood (2021) 138 (Supplement 1): 3338.

https://doi.org/10.1182/blood-2021-151579

Published: 2021

Journal Articles

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study

Blood (2021) 138 (Supplement 1): 3682.

https://doi.org/10.1182/blood-2021-154179

Published: 2021

Journal Articles

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-133855

Published: 2020

Journal Articles

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Jorge E. Cortes, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Sangmin Lee, MD, Maria R. Baer, MD, Kim-Hien Dao, DO, PhD, Shira Dinner, MD, Jay Yang, MD, William B. Donnellan, MD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Christian Recher, MD PhD, Patrick Kelly, MD, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 674.

https://doi.org/10.1182/blood-2019-124360

Published: 2019

Journal Articles

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 231.

https://doi.org/10.1182/blood-2019-123920

Published: 2019

Journal Articles

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Blood (2019) 134 (Supplement_1): 846.

https://doi.org/10.1182/blood-2019-122980

Published: 2019

Journal Articles

Clonal Hematopoiesis in Older Women with Extremely Skewed, Non-Random X-Inactivation Is Associated with Previous Cardiovascular and Cerebrovascular Events

Emily Marre, MPH, Julia Erin Wiedmeier, MD MPH, Zhenzhen Zhang, PhD, Hyunjung Lee, Dana Parker, Kelsey Westerlund, Christopher A. Eide, Catherine Kato, Maros Ferencik, MD PhD, Brian J. Druker, MD, Kim-Hien Dao, DO, PhD

Blood (2018) 132 (Supplement 1): 2574.

https://doi.org/10.1182/blood-2018-99-120323

Published: 2018

Journal Articles

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

Naval G. Daver, MD, Marina Kremyanskaya, MD PhD, Casey O'Connell, MD, Kim-Hien Dao, DO,PhD, Stephen T Oh, MD PhD, Aaron T. Gerds, MDMS, Srdan Verstovsek, MD PhD, Sue Erickson-Viitanen, PhD, Feng Zhou, Albert Assad, MD, Abdulraheem Yacoub, MD

Blood (2018) 132 (Supplement 1): 353.

https://doi.org/10.1182/blood-2018-99-111338

Published: 2018

Journal Articles

Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Kim-Hien Dao, DO,PhD, Robert H. Collins, MD, Jorge E. Cortes, MD, Michael W. Deininger, MD PhD, Brian J. Druker, MD, Jason R. Gotlib, MDMS, Tara Alyson Macey, PhD, Stephen T Oh, MD PhD, Jeffrey W. Tyner, PhD, Elliott F. Winton, MD

Blood (2018) 132 (Supplement 1): 350.

https://doi.org/10.1182/blood-2018-99-119476

Published: 2018

Journal Articles

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1 m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Justin Watts, MD, Maria R. Baer, MD, Jay Yang, MD, Shira Dinner, MD, Sangmin Lee, MD, Karen Seiter, MD, Thomas Prebet, MD PhD, Gary J. Schiller, MD, Paul Brent Ferrell, Jr., MD, Kim-Hien Dao, DO, PhD, Hagop M. Kantarjian, MD, Patrick Kelly, MD, Ping Li, PhD, Jennifer Sweeney, Courtney Watson, Hesham Mohamed, MD, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 1453.

https://doi.org/10.1182/blood-2018-99-114263

Published: 2018

Journal Articles

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, William Sun, PhD, Ahmad Naim, MD, Smitha Svaraman, PhD, Jessy Gao, MA, Jason R. Gotlib, MD, Vikas Gupta, MD FRCP, FRCPath, Kim-Hien Dao, DO, PhD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 1949.

https://doi.org/10.1182/blood.V128.22.1949.1949

Published: 2016

Journal Articles

The RNA Editase ADAR1 Promotes Malignant Progenitor Reprogramming in Chronic Myeloid Leukemia.

Qingfei Jiang, Ph.D., Leslie Crews-Robertson, PhD, Christian L Barrett, Ph.D., Hyn-June Chun, Angela C. Court-Recart, M.S., Daniel J Goff, PhD, Mark D. Minden, MD, PhD, Anil Sadarangani, Ph.D., Jessica Rusert, B.S., Kim-Hien Dao, DO, PhD, Sheldon R Morris, MD, MPH, Lawrence S. B. Goldstein, Ph.D., Marco A. Marra, PhD, Kelly A Frazer, Ph.D., Catriona Jamieson, MD, PhD

Blood (2012) 120 (21): 2772.

https://doi.org/10.1182/blood.V120.21.2772.2772

Published: 2012

Journal Articles

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Daniel W. Sherbenou, Oliver Hantschel, Ines Kaupe, Stephanie Willis, Thomas Bumm, Lalita P. Turaga, Thoralf Lange, Kim-Hien Dao, Richard D. Press, Brian J. Druker, Giulio Superti-Furga, Michael W. Deininger

Blood (2010) 116 (17): 3278–3285.

https://doi.org/10.1182/blood-2008-10-183665

Published: 2010

Includes: Supplemental data

NARROW

ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Inhibiting Drp1 Dependent Mitochondrial Fission

A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Altering Drp1-Dependent Mitochondrial Fission and Metabolism

Inhibition of ERK1/2 Reverses Venetoclax-Induced Autophagy to Overcome Resistance in Acute Myeloid Leukemia

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

A Phase 1 Study Evaluating ASTX727 (decitabine and cedazuridine) and Venetoclax Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction Chemotherapy

ERK1/2 Inhibition Overcomes Resistance in Acute Myeloid Leukemia (AML) and Alters Mitochondrial Dynamics

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Clonal Hematopoiesis in Older Women with Extremely Skewed, Non-Random X-Inactivation Is Associated with Previous Cardiovascular and Cerebrovascular Events

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1 m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

The RNA Editase ADAR1 Promotes Malignant Progenitor Reprogramming in Chronic Myeloid Leukemia.

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only